Shaanxi Micot shares nearly double in Hong Kong trading debut
Shares of drugmaker Shaanxi Micot Pharmaceutical Technology Co. Ltd. (2335.HK) jumped in their Hong Kong trading debut on Wednesday, after the company raised HK$989 million ($126 million) by selling about…
HJ Science tumbles in Hong Kong trading debut
Shares of clinical-stage biotechnology company HJ Science Co. Ltd. (6132.HK) opened flat in their Hong Kong trading debut on Tuesday, but quickly headed south and ended their first day down…
Jiangxi Bio launches $60 million IPO, warns of sharp profit decline this year
Human tetanus antitoxin (TAT) maker Jiangxi Institute of Biological Products Inc. (6915.HK) launched its Hong Kong IPO on Monday, offering 36.23 million shares for HK$13.06 each to raise HK$473 million…
WuXi AppTec sues to get its name removed from U.S. blacklist
Pharmaceutical services provider WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) has sued the U.S. Defense Department, seeking to have its name removed from the department’s list of Chinese companies with military…
BRIEF: Shimai Pharma gets CSRC nod for Hong Kong IPO
Zhejiang Shimai Pharmaceutical Co. Ltd., a developer of T-cell engager (TCE) therapies, has been cleared by the China Securities Regulatory Commission (CSRC) for its overseas listing, marking an important step…
BRIEF: WuXi Biologics maintains full-year revenue guidance for up to 17% growth
Drug development services company WuXi Biologics (Cayman) Inc. (2269.HK) announced on Sunday that it had secured 69 new integrated projects as of April 30, with approximately two-thirds originating from clients…
BRIEF: So-Young revenue jumps on aesthetic center growth as loss widens
Medical aesthetics platform So-Young International Inc. (SY.US) reported on Friday that its first-quarter revenue rose 45.6% year-on-year to 433 million yuan ($64 million), mainly driven by growth in its self-operated aesthetic medical…